U.S., Dec. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07293546) titled 'Phase 1/2 Study of FRF-001, an AAV-9 Gene Therapy, in Patients With FOXG1 Syndrome (FS)' on Dec. 16.
Brief Summary: The goal of this clinical trial is to learn if FRF-001 is a safe, tolerable, and efficacious treatment for children and adults with FOXG1 syndrome.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
FOXG1 Syndrome
Intervention:
GENETIC: FRF-001
AAV-9 gene therapy delivered by intracerebroventricular injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: FOXG1 Research Foundation
Disclaimer: Curated by HT Syndication....